Source: CureToday articles
Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.
Recent Content
- MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy
- Day 3: Top Takeaways From ASCO25
- NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction
- NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk
- NLA 2025: Practical Strategies for Identifying the Right Patient for Incretin Therapy
- Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer
- Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups
- Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer
- NLA 2025: Understanding the Impact of Omega-3 Fatty Acids on LDL Cholesterol
- Harnessing the Tumor Microenvironment for Enhanced Cancer Treatment